4//SEC Filing
HEILBRUNN KENNETH R 4
Accession 0001209191-04-027887
CIK 0000920465other
Filed
May 24, 8:00 PM ET
Accepted
May 25, 9:50 PM ET
Size
10.7 KB
Accession
0001209191-04-027887
Insider Transaction Report
Form 4
HEILBRUNN KENNETH R
VP of Clinical Development
Transactions
- Award
Stock Options (right to buy)
2004-05-21+80,000→ 80,000 totalExercise: $2.96Exp: 2014-05-21→ Common Stock (80,000 underlying) - Other
Common Stock
2004-03-31$1.48/sh+937$1,386→ 9,485 total
Footnotes (2)
- [F1]Acquired pursuant to the Company?s Employee Stock Purchase Plan.
- [F2]50% of the options vest on the date that the Company receives approval to market its lead drug candidate for the treatment of lupus and 1/24 of the remaining options vest at the end of each month thereafter until all of the options are vested. Notwithstanding the foregoing, if marketing approval is not obtained between the grant date and the three year anniversary of the grant date, then 100% of the options will vest on the three year anniversary of the grant date.
Issuer
LA JOLLA PHARMACEUTICAL CO
CIK 0000920465
Entity typeother
Related Parties
1- filerCIK 0001237530
Filing Metadata
- Form type
- 4
- Filed
- May 24, 8:00 PM ET
- Accepted
- May 25, 9:50 PM ET
- Size
- 10.7 KB